Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PL MLP

Drug Profile

PL MLP

Alternative Names: LPMX-1; LPMX-2; PL-MLP; Promitil

Latest Information Update: 20 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Lipomedix Pharmaceuticals
  • Class Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours
  • Preclinical Bladder cancer

Most Recent Events

  • 29 Mar 2019 Efficacy and pharmacokinetics data from a phase I trial in Solid tumours presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
  • 03 Jan 2019 Lipomedix Pharmaceuticals initiates enrolment in a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in Israel (NCT03823989)
  • 23 Jul 2018 PL MLP is still in phase I trials for Solid-tumours (Late-stage disease) in Israel
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top